MedTrace Logo

Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose

NCT00347828 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2006-07-04

No results posted yet for this study

Summary

The purpose of this study is to analyze the effect of Zymar and Vigamox on ocular surface bacteria. We believe that Zymar will eradicate more ocular surface bacteria than Vigamox.

Conditions

Interventions

DRUG

Moxifloxacin ophthalmic solution 0.5%

DRUG

Gatifloxacin ophthalmic solution 0.3%

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Ophthalmic Consultants of Boston

    lead OTHER

Principal Investigators

  • Michael B Raizman, B.A./M.D. · Ophthalmic Consultants of Boston

  • Sandra Y Cho, B.A./M.D. · New England Eye Center/Tufts-New England Medical Center

  • Rahul Mandiga, B.S. · New England Eye Center/Tufts-New England Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-06-30
Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00347828 on ClinicalTrials.gov